A federal judge has dismissed legal challenges to the Medicare negotiation program brought by Bristol Myers Squibb and Johnson & Johnson, ruling that their claims of unconstitutionality are unfounded.
Bristol Myers Squibb’s products Eliquis and Farxiga were both named among the first 10 drugs eligible for Medicare negotiation, as were Xarelto, Imbruvica and Stelara from Johnson & Johnson. The ...
April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot ...
S&P 500 operating EPS growth was solid at 6.4% in Q1, but critics argue that excluding profits from top tech stocks shows less impressive growth. Bristol-Myers Squibb faces a soft growth outlook ...
Bristol-Myers Squibb Company BMY reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus Estimate of a loss of $4.53 per share. In the year-ago quarter, BMY posted adjusted ...
Expenses related to acquisitions recently weighed down Bristol Myers' earnings results. The company, however, still generates strong free cash flow. Its high debt load could turn off some risk ...
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Bristol Myers Squibb(NYSE: BMY) pays investors an attractive dividend, which yields an incredibly high rate of 5.5%. That's nearly four times the S&P 500 average of 1.4%. At such a high rate ...